Related Experiment Video
Updated: May 5, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Newer anticoagulants for non-valvular atrial fibrillation
Joseph M Harburger1, Wilbert S Aronow
1Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA. wsaronow@aol.com.
Insights
Warfarin is a stroke prevention drug for atrial fibrillation but has drawbacks. New anticoagulants offer safer alternatives for non-valvular atrial fibrillation patients.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Non-valvular atrial fibrillation (NVAF) increases stroke and embolism risk.
- Warfarin effectively reduces stroke risk in NVAF patients with risk factors.
- Warfarin's limitations include monitoring needs, drug/food interactions, and bleeding risks, leading to underutilization.
Purpose of the Study:
- To review the established use of warfarin for stroke prevention in NVAF.
- To discuss the development and approval of novel anticoagulant agents for NVAF.
- To compare warfarin with newer agents in managing NVAF.
Main Methods:
- Literature review of warfarin's efficacy and limitations in NVAF.
- Analysis of clinical trial data for newly approved anticoagulants.
- Comparative assessment of safety, efficacy, and monitoring requirements.
Main Results:
- Warfarin is a proven stroke preventative but requires careful management.
- Two novel anticoagulants are FDA-approved for NVAF, with others in development.
- New agents offer potential advantages over warfarin, including reduced monitoring and fewer interactions.
Conclusions:
- Warfarin remains a treatment option for NVAF, despite its challenges.
- Novel anticoagulants represent significant advancements in NVAF management.
- The evolving landscape of anticoagulation offers improved therapeutic options for patients with NVAF.
Abstract:
Non-valvular atrial fibrillation is a recognized risk factor for stroke and systemic embolism. It has been clearly established that warfarin reduces the risk of stroke and systemic embolism in persons with atrial fibrillation and additional risk factors for stroke. The use of warfarin, however, requires frequent monitoring, and there is great variability in patient response to warfarin. Warfarin interacts with several medications and foods. In addition, warfarin use portends a significant risk of bleeding. For these reasons, warfarin is frequently not prescribed to persons for whom the drug would provide a clear benefit. Over the past decade, attempts have been made to develop drugs that are at least as safe and effective as warfarin for the treatment of atrial fibrillation that do not require monitoring nor have as many interactions. Initial studies of compounds in this regard ultimately failed due to safety concerns, but over the past two years two novel agents have been approved by the United States Food and Drug Association for anticoagulation in non-valvular atrial fibrillation, another drug is under review, and additional compounds are being studied. This article will review the use of warfarin and these new agents in the treatment of non-valvular atrial fibrillation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...